You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Skin conditions
  5. Eczema

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

  • Technology appraisal guidance
  • Reference number: TA814
  • Published:  03 August 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final draft guidance
  2. Draft guidance
  3. Assessment report sent for information
  4. Invitation to participate

History

Documents created during the development process.

Final draft guidance

  • Final draft guidance

  • Final appraisal document (PDF 172 KB)

    Published:
    29 June 2022
  • Committee papers (PDF 1.08 MB)

    Published:
    29 June 2022
  • Public committee slides (PDF 1.63 MB)

    Published:
    29 June 2022

Draft guidance

  • Draft guidance

  • Appraisal consultation document (PDF version) (PDF 300 KB)

    Published:
    08 April 2022
  • Appraisal consultation document (online commenting)

  • Committee papers (PDF 15.52 MB)

    Published:
    08 April 2022
  • Public committee slides (PDF 1.65 MB)

    Published:
    08 April 2022

Assessment report sent for information

  • Final protocol (PDF 862 KB)

    Published:
    07 January 2022

Invitation to participate

  • Equality impact assessment (Scoping) (PDF 131 KB)

    Published:
    05 August 2021
  • Final protocol (PDF 862 KB)

    Published:
    05 August 2021
  • Final stakeholder list (PDF 182 KB)

    Published:
    05 August 2021
  • Final scope (PDF 225 KB)

    Published:
    05 August 2021
Back to top